+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cannabis Pharmaceuticals Market Size, Share & Trends Analysis Report by Brand Type (Sativex, Epidiolex, Other Brands), Region (North America, Europe, Asia-Pacific), and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 150 Pages
  • January 2024
  • Region: Global
  • Grand View Research
  • ID: 5534066
The global cannabis pharmaceutical market is expected to reach USD 11.53 billion by 2030. The market is expected to expand at a CAGR of 32.6% from 2024 to 2030.The rise in applications of cannabis for various indications, including sleep disorders, pain, inflammation, epilepsy, anorexia, multiple sclerosis, and schizophrenia, is driving the market growth. Demand for processed, quantified, and packaged cannabis products for medical purposes is significantly increasing. Moreover, consumer and regulatory acceptance of cannabis products is increasing, positively impacting the market growth. For instance, regulatory approval of cannabis-based products such as Epidiolex and Sativex is improving the perspectives of both patients and physicians regarding the use of cannabis.

An increasing number of research and development activities and product approvals are anticipated to drive market growth over the forecast period. For instance, in August 2021, GW Pharmaceutical received approval for using EPIDYOLEX to treat tuberous sclerosis complex seizures from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Such approvals are estimated to increase demand for cannabis in the pharmaceutical industry.

The rising number of clinical trials signifying the positive effects of utilizing cannabis pharmaceuticals for treating various medical conditions, such as multiple sclerosis, epilepsy, chronic pain, and cancer, is a major factor boosting market growth. Positive results provided by clinical trials help to change the perspective of patients & healthcare professionals toward cannabis and pharmaceutical drugs developed using cannabis. For instance, as per the data provided by ClinicalTrials.gov, as of 2022, there are around 722 studies for Sativex that are active, either recruiting, not recruiting, or enrolling by invitation.

Cannabis Pharmaceuticals Market Report Highlights

  • By brand type, epidiolex segment held the largest revenue share of 98.5% in the global market in 2023. Growing approval of the drug for the treatment of severe forms of epilepsy, Dravet syndrome, Lennox Gastaut syndrome, and Tuberous Sclerosis Complex in various countries is supporting segment growth
  • Europe accounted for the largest revenue share in 2023, owing to growing number of medical cannabis users, along with the presence of major manufacturers in the region
  • Latin American markets are estimated to grow at the fastest rate during the forecast period. This can be attributed to growing legalization and favorable guidelines toward using cannabis pharmaceuticals in the region


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Cannabis Pharmaceuticals Market: Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Brand Type
1.2.2. Regional Scope
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Cannabis Pharmaceuticals Market: Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Brand type outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Cannabis Pharmaceuticals Market: Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Cannabis Pharmaceuticals Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Cannabis Pharmaceuticals Market: Brand Type Estimates & Trend Analysis
4.1. Brand Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Cannabis Pharmaceuticals Market by Brand Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Sativex
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Epidiolex
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Other Brands
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Cannabis Pharmaceuticals Market: Regional Estimates & Trend Analysis
5.1. Regional Market Share Analysis, 2023 & 2030
5.2. Regional Market Dashboard
5.3. Global Regional Market Snapshot
5.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
5.5. North America
5.5.1. U.S.
5.5.1.1. Key country dynamics
5.5.1.2. Regulatory framework
5.5.1.3. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2. Canada
5.5.2.1. Key country dynamics
5.5.2.2. Regulatory framework
5.5.2.3. Canada market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Europe
5.6.1. UK
5.6.1.1. Key country dynamics
5.6.1.2. Regulatory framework
5.6.1.3. UK market estimates and forecasts 2018 to 2030 (USD Million)
5.6.2. Germany
5.6.2.1. Key country dynamics
5.6.2.2. Regulatory framework
5.6.2.3. Germany market estimates and forecasts 2018 to 2030 (USD Million)
5.6.3. France
5.6.3.1. Key country dynamics
5.6.3.2. Regulatory framework
5.6.3.3. France market estimates and forecasts 2018 to 2030 (USD Million)
5.6.4. Italy
5.6.4.1. Key country dynamics
5.6.4.2. Regulatory framework
5.6.4.3. Italy market estimates and forecasts 2018 to 2030 (USD Million)
5.6.5. Switzerland
5.6.5.1. Key country dynamics
5.6.5.2. Regulatory framework
5.6.5.3. Spain market estimates and forecasts 2018 to 2030 (USD Million)
5.6.6. Czech Republic
5.6.6.1. Key country dynamics
5.6.6.2. Regulatory framework
5.6.6.3. Norway market estimates and forecasts 2018 to 2030 (USD Million)
5.6.7. Croatia
5.6.7.1. Key country dynamics
5.6.7.2. Regulatory framework
5.6.7.3. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
5.6.8. Poland
5.6.8.1. Key country dynamics
5.6.8.2. Regulatory framework
5.6.8.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
5.6.9. Netherlands
5.6.9.1. Key country dynamics
5.6.9.2. Regulatory framework
5.6.9.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Asia-Pacific
5.7.1. Japan
5.7.1.1. Key country dynamics
5.7.1.2. Regulatory framework
5.7.1.3. Japan market estimates and forecasts 2018 to 2030 (USD Million)
5.7.2. Australia
5.7.2.1. Key country dynamics
5.7.2.2. Regulatory framework
5.7.2.3. Australia market estimates and forecasts 2018 to 2030 (USD Million)
5.7.3. South Korea
5.7.3.1. Key country dynamics
5.7.3.2. Regulatory framework
5.7.3.3. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
5.7.4. New Zealand
5.7.4.1. Key country dynamics
5.7.4.2. Regulatory framework
5.7.4.3. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Latin America
5.8.1. Brazil
5.8.1.1. Key country dynamics
5.8.1.2. Regulatory framework
5.8.1.3. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
5.8.2. Mexico
5.8.2.1. Key country dynamics
5.8.2.2. Regulatory framework
5.8.2.3. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
5.8.3. Argentina
5.8.3.1. Key country dynamics
5.8.3.2. Regulatory framework
5.8.3.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
5.8.4. Colombia
5.8.4.1. Key country dynamics
5.8.4.2. Regulatory framework
5.8.4.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
5.8.5. Uruguay
5.8.5.1. Key country dynamics
5.8.5.2. Regulatory framework
5.8.5.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
5.8.6. Chile
5.8.6.1. Key country dynamics
5.8.6.2. Regulatory framework
5.8.6.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
5.8.7. Peru
5.8.7.1. Key country dynamics
5.8.7.2. Regulatory framework
5.8.7.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
5.9. MEA
5.9.1. Israel
5.9.1.1. Key country dynamics
5.9.1.2. Regulatory framework
5.9.1.3. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, by Key Market Participants
6.2. Company/Competition Categorization
6.3. Vendor Landscape
6.3.1. Jazz Pharmaceuticals, Inc.
6.3.1.1. Company overview
6.3.1.2. Financial performance
6.3.1.3. Product benchmarking
6.3.1.4. Strategic initiatives
6.3.2. AbbVie, Inc.
6.3.2.1. Company overview
6.3.2.2. Financial performance
6.3.2.3. Product benchmarking
6.3.2.4. Strategic initiatives
6.3.3. Insys Therapeutics, Inc.
6.3.3.1. Company overview
6.3.3.2. Financial performance
6.3.3.3. Product benchmarking
6.3.3.4. Strategic initiatives
6.3.4. Bausch Health Companies, Inc.
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America cannabis pharmaceuticals market, by region, 2018-2030 (USD Million)
Table 3 North America cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 4 U.S. cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 5 Canada cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 6 Europe cannabis pharmaceuticals market, by region, 2018-2030 (USD Million)
Table 7 Europe cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 8 Germany cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 9 UK cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 10 France cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 11 Italy cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 12 Switzerland cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 13 Czech Republic cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 14 Croatia cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 15 Poland cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 16 Netherland cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 17 Asia-Pacific cannabis pharmaceuticals market, by region, 2018-2030 (USD Million)
Table 18 Asia-Pacific cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 19 Japan cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 20 South Korea cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 21 Australia cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 22 New Zealand cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 23 Latin America cannabis pharmaceuticals market, by region, 2018-2030 (USD Million)
Table 24 Latin America cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 25 Brazil cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 26 Mexico cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 27 Argentina cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 28 Colombia cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 29 Uruguay cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 30 Chile cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 31 Peru cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 32 MEA cannabis pharmaceuticals market, by region, 2018-2030 (USD Million)
Table 33 MEA cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
Table 34 Israel cannabis pharmaceuticals market, by brand type, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Cannabis pharmaceuticals market: market outlook
Fig. 9 Cannabis pharmaceuticals competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Cannabis pharmaceuticals market driver impact
Fig. 13 Cannabis pharmaceuticals market restraint impact
Fig. 14 Cannabis pharmaceuticals market: Brand type movement analysis
Fig. 15 Cannabis pharmaceuticals market: Brand type outlook and key takeaways
Fig. 16 Sativex market estimates and forecast, 2018-2030
Fig. 17 Epidiolex market estimates and forecast, 2018-2030
Fig. 18 Other brands market estimates and forecast, 2018-2030
Fig. 19 Global cannabis pharmaceuticals market: Regional movement analysis
Fig. 20 Global cannabis pharmaceuticals market: Regional outlook and key takeaways
Fig. 21 North America, by country
Fig. 22 North America market estimates and forecasts, 2018-2030
Fig. 23 U.S. market estimates and forecasts, 2018-2030
Fig. 24 Canada market estimates and forecasts, 2018-2030
Fig. 25 Europe market estimates and forecasts, 2018-2030
Fig. 26 UK market estimates and forecasts, 2018-2030
Fig. 27 Germany market estimates and forecasts, 2018-2030
Fig. 28 France market estimates and forecasts, 2018-2030
Fig. 29 Italy market estimates and forecasts, 2018-2030
Fig. 30 Poland market estimates and forecasts, 2018-2030
Fig. 31 Croatia market estimates and forecasts, 2018-2030
Fig. 32 Czech Republic market estimates and forecasts, 2018-2030
Fig. 33 Switzerland market estimates and forecasts, 2018-2030
Fig. 34 Netherland market estimates and forecasts, 2018-2030
Fig. 35 Asia-Pacific market estimates and forecasts, 2018-2030
Fig. 36 Japan market estimates and forecasts, 2018-2030
Fig. 37 South Korea market estimates and forecasts, 2018-2030
Fig. 38 New Zealand market estimates and forecasts, 2018-2030
Fig. 39 Australia market estimates and forecasts, 2018-2030
Fig. 40 Latin America market estimates and forecasts, 2018-2030
Fig. 41 Brazil market estimates and forecasts, 2018-2030
Fig. 42 Mexico market estimates and forecasts, 2018-2030
Fig. 43 Argentina market estimates and forecasts, 2018-2030
Fig. 44 Colombia market estimates and forecasts, 2018-2030
Fig. 45 Uruguay market estimates and forecasts, 2018-2030
Fig. 46 Chile market estimates and forecasts, 2018-2030
Fig. 47 Peru market estimates and forecasts, 2018-2030
Fig. 48 Middle East and Africa market estimates and forecasts, 2018-2030
Fig. 49 Israel market estimates and forecasts, 2018-2030

Companies Mentioned

  • Jazz Pharmaceuticals, Inc.
  • AbbVie, Inc.
  • Insys Therapeutics, Inc.
  • Bausch Health Companies, Inc.

Methodology

Loading
LOADING...